We treated two pancreatic cancer cell lines (Miapaca2, PDA) and lung cancer cell lines (H1299, H460) with the PARP inhibitor, LT626 (0–10 μM) for five days and cell viability was measured by MTT assay. This evidence concerns the gene PARP1 and lung carcinoma.